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Although abnormal metabolic regulation is a critical determinant of cancer cell 
behavior, it is still unclear how an altered balance between ATP production and 
consumption contributes to malignancy. Here the results show that disruption of 
this energy balance efficiently suppresses aggressive malignant gliomas driven 
by mTOR complex 1 (mTORC1) hyperactivation. In a mouse glioma model, 
mTORC1 hyperactivation induced by conditional Tsc1 deletion increased 
numbers of glioma-initiating cells (GICs) in vitro and in vivo. Metabolic analysis 
revealed that mTORC1 hyperactivation enhanced mitochondrial biogenesis, as 
evidenced by elevations in oxygen consumption rate (OCR) and ATP production. 
Inhibition of mitochondrial ATP synthetase was more effective in repressing 
sphere formation by Tsc1-deficient glioma cells than that by Tsc1-competent 
glioma cells, indicating a crucial function for mitochondrial bioenergetic capacity 
in GIC expansion.  
To translate this observation into the development of novel therapeutics 
targeting malignant gliomas, I screened drug libraries for small molecule 
compounds showing greater efficacy in inhibiting the proliferation/survival of 
Tsc1-deficient cells compared to controls. Several compounds able to 
preferentially inhibit mitochondrial activity, dramatically reducing ATP levels 
and blocking glioma sphere formation were identified. In human patient-derived 
glioma cells, nigericin, which reportedly suppresses cancer stem cell properties, 
induced AMPK phosphorylation that was associated with mTORC1 inactivation 
and induction of autophagy, and led to a marked decrease in sphere formation 
with loss of GIC marker expression. Furthermore, malignant characteristics of 
human glioma cells were markedly suppressed by nigericin treatment in vivo.  
Thus, targeting mTORC1-driven processes, particularly those involved in 
maintaining a cancer cell’s energy balance, may be an effective therapeutic 
strategy for glioma patients. 
 
 
mTORC1 hyperactivation expands mouse GICs in vitro and in vivo  
To investigate the role of mTORC1 in GIC expansion, the previously described 
mouse glioma model in which mTORC1 is activated by a TAM-inducible system 
was used. After gliomas had developed, huKO+ cells were collected and glioma 
cells isolated by flow cytometry. huKO+ cells were cultured under standard NSPC 
culture conditions, Tsc1 deficiency significantly increased the number of spheres 
formed (Fig.1), indicating that the sphere-forming cells had expanded upon 
mTORC1 activation. To evaluate the tumor-initiating capacity of glioma cells in 
vivo, recipient mice were inoculated with 100, 1,000 or 10,000 freshly isolated 
huKO+ glioma cells. Tsc1 deficiency promoted tumor development and 
accelerated the death of recipients compared to Tsc1-competent glioma cells 
(Fig.2). When as few as 10 huKO+ cells were transplanted, only Tsc1-deficient 
glioma cells were capable of producing gliomas, but not control cells. Thus, GIC 
frequency is increased in vivo by mTORC1 activation.  
	
mTORC1 activation causes growth factor-independent proliferation of 
mouse GICs  
First, 4-OHT efficiently induced Tsc1 deletion in these sphere cells was 
confirmed by western blotting(Fig.3). However, unexpectedly, there was no 
difference in the number of spheres formed by control and Tsc1-deficient cells 
cultured in the presence of EGF+FGF2 (Fig.4). This may be due to differences 
between conditions in vitro and in vivo. Although level of phosphorylation in 4E-
BP1 was slightly up-regulated, those of S6 and p70S6K were almost normal in 
Tsc1-deficient glioma cells (Fig.3). It is speculated that, mTORC1 is fully 
activated when cytokines are abundant, and that levels of these factors are much 
higher in vitro than in vivo, therefore, Tsc1 deletion might not be able to further 
enhance such signaling in this culture condition. When control and Tsc1-deficient 
glioma cells were cultured in the absence of EGF+FGF2, the size and number of 
spheres formed in these control glioma cell cultures was decreased compared to 
those in control cultures containing growth factors, however, Tsc1-deficient 
glioma cells showed comparable sphere forming capacity in presence and 
absence of these growth factors (Fig.4). Thus, mTORC1 hyperactivation 
maintains sphere-forming capacity even when growth factors are withdrawn. In 
addition, although levels of S6 and 4E-BP phosphorylation in control glioma cells 
cultured without growth factors were lower than those with growth factors, such 
down-regulation of phosphorylation due to growth factor depletion was not 
observed in Tsc1-deficient cells (Fig.3). Results did not show a remarkable 
change in the expression of Olig2, a glioma stem cell marker, in Tsc1-deficient 
glioma cells (Fig.5), which assume that Tsc1 deficiency promotes the 
proliferation and/or survival of GICs.  
	
Increased sensitivity of Tsc1-deficient glioma cells to glucose depletion  
metabolite levels were assessed in control and Tsc1-deficient glioma cells in 
culture in vitro using CE-TOFMS. Several metabolites in the glycolytic pathway, 
including (G6P), (F1,6BP), (3PGA), and (PEP), were significantly up-regulated 
(Fig.6). The same was true for components of the pentose phosphate pathway, 
including (6PGL), (Ru5P), (S7P) (Fig.6). These findings suggested that glucose 
metabolism might be stimulated in Tsc1-deficient cells. Gene expression levels 
showed that mRNAs encoding glycolytic enzymes such as glucose transporter 1, 
hexokinase2, and pyruvate kinase M2 were all elevated by mTORC1 activation 
(Fig.7). These data indicate that mouse glioma cells experiencing mTORC1 
hyperactivation show increased dependence on glucose. 
 
Enhanced mitochondrial ATP production supports mTORC1-driven GIC 
expansion 
Metabolomics analysis showed that lactate levels in glioma cells were not 
significantly affected by Tsc1 deletion (Fig.6). These data suggested that the 
increased glucose uptake exhibited by Tsc1-deficient cells might contribute to 
enhanced mitochondrial OXPHOS rather than to the production of lactate via 
typical glycolysis. To determine OXPHOS in these cells, OCR was evaluated and 
it was significantly increased in Tsc1-deficient glioma cells (Fig.8). In addition, 
the expression levels of mitochondria-associated genes were up-regulated by 
Tsc1 deletion (Fig.9). ATP levels were increased in Tsc1-deficient cells compared 
to controls (Fig.10, left). To assess whether this increase in ATP in Tsc1-deficient 
cells was in fact due to enhanced OXPHOS, the cells were treated with 
oligomycin, an ATP synthetase inhibitor. Although, oligomycin had only a 
modest effect on ATP levels in control cells, it dramatically reduced ATP levels 
in Tsc1-deficient cells (Fig.10, right). oligomycin also profoundly suppressed 
sphere formation by Tsc1-deficient cells compared to controls (Fig.11).  
 
Drug screening to identify small molecule compounds that can suppress 
sphere formation by Tsc1-deficient mouse glioma cells 
The new application of a known drug, called drug repositioning or drug 
repurposing, has been a beneficial approach for developing novel therapies for 
human diseases. I assessed whether this mouse glioma model would be useful for 
drug screening to identify known compounds able to specifically inhibit the 
aggressive phenotypes of glioma cells. To this end, I evaluated the effects of 
numerous small molecule compounds from commercially available existing drug 
libraries (a total of 1,301 compounds) on the proliferation/survival of control and 
Tsc1-deficient mouse glioma cells. First the inhibitory effect was estimated for 
each compound on both types of cells, and then the ratio of the inhibitory effect 
on Tsc1-deficient cells compared to its effect on control cells was calculated; this 
ratio was termed the "Index for drug sensitivity of Tsc1-deficient cells". Most 
compounds screened exhibited an Index of about 1.0 ± 0.5 (Fig.12), indicating 
that they had equal effects on control and Tsc1-deficient cells. Several compounds 
showed low Index values, suggesting that these drugs were less effective in 
inhibiting the growth of Tsc1-deficient cells than that of control cells. For 
example, EGFR inhibitors gefitinib and erlotinib showed less efficacy in Tsc1-
deficient cells than in control cells. Several genotoxic reagents, including 
mitoxantrone and topotecan, were also less efficacious in Tsc1-deficient cells. In 
contrast to the above, several compounds were identified that were highly 
effective in inhibiting the growth of Tsc1-deficient glioma cells compared to that 
of control cells. From the first screening, 13 drugs were selected that showed 
reproducible increased efficacy in Tsc1-deficient cells compared to controls.  
Next, I screened the selected compounds for those that caused a greater 
reduction in intracellular ATP levels in Tsc1-deficient cells, based on the previous 
observation that oligomycin treatment or glucose starvation triggered a 
significant reduction in ATP in the former. I found that 5 drugs (nigericin, A23187, 
auranofin, rottlerin and valinomycin) clearly reduced intracellular ATP levels 
when used at less than 20 µM (Fig.13). I confirmed that these 5 compounds also 
had a greater suppressive effect on sphere formation by Tsc1-dificent glioma cells 
than on that by control cells (Fig.14), suggesting that the screening system could 
efficiently identify drug candidates in therapeutic approach for mTORC1-driven 
glioma.  
	 To investigate the selected compounds effect on human GBM cells, I 
applied each agent to human patient-derived GBM cell lines (TGS-01 and TSG-
04 cells). I found that all the 5 drug compounds reduced ATP in TGS-01 cells 
compared to untreated GBM cells (Fig.15). All compounds also induced 
abnormality in mitochondrial membrane potential (Fig.16). This means that 
treatment with most of these selected compounds might drive down intracellular 
ATP levels by interfering with mitochondrial ATP production.  
Since it was previously reported that nigericin and valinomycin affect 
mitochondrial respiratory chain, Conferment of their effects was performed. After 
downregulation of OCR by ATP synthase inhibition (oligomycin treatment), it 
was recovered by valinomycin (as expected) (Fig.17). In contrast, nigericin 
treatment blocked the respiratory chain and maintained its suppression even after 
addition of FCCP (an uncoupler), indicating that nigericin is an efficient inhibitor 
of mitochondrial bioenergetics.  
 
Nigericin suppresses malignant phenotypes of human patient-derived GBM 
cells  
Next I investigated whether the selected compounds might have therapeutic 
potential for human GBM. Among the candidates, nigericin has previously been 
selected by a drug screening program as being capable of targeting cancer stem 
cell properties. Therefore, I focused on nigericin to determine if this compound 
could have advantage in suppression of malignant phenotypes of human GBM 
cells in vitro and in vivo. I found that nigericin could indeed effectively reduce 
sphere formation by human GBM cells in culture (Fig.18). While nigericin 
treatment blocked the cell cycle, (Fig.19), it did not induce significant apoptosis 
(Fig.20). Mitochondrial ROS were up-regulated in glioma cells (Fig.21), 
indicating that nigericin induces mitochondrial dysfunction. Moreover, 
expression levels of the glioma stem cell markers, Olig2 and CD133, were 
dramatically downregulated during culture with nigericin (Fig.22, 23). These data 
indicate that nigericin suppresses proliferation of GBM cells, associated with the 
loss of stem cell properties. nigericin clearly triggered AMPK phosphorylation 
that was associated with marked inhibition of phosphorylated S6K and 4EBP1 
(Fig.24), suggesting that downregulation of ATP levels stimulates an anti-tumor 
signaling cascade that includes AMPK activation and mTORC1 inactivation. 
mTOR inhibition and AMPK activation are both known to induce autophagy, as 
determined by an observed increase in the LC3-II/LC3-I ratio (Fig.24). To 
investigate whether nigericin inhibits sphere formation due to abnormality in 
energy control, concentration of sodium pyruvate was increased in culture media, 
because pyruvic acid supplies energy to cells through the OXYPHOS in the 
presence of oxygen. As a result, addition of sodium pyruvate mitigated the 
inhibitory effect of low concentration, but not higher concentration (>0.1 µM), of 
nigericin on sphere formation (Fig.25). These data suggest that low dose of 
nigericin inhibits sphere formation due to partial, but not complete, impairment 
of mitochondrial energy production.  
Lastly, I determined whether nigericin administration could inhibit glioma 
growth in vivo. Immunocompromised mice were injected with human GBM cells 
and tumor development was monitored. Indeed, tumor volume was greatly 
reduced in nigericin-treated recipient mice (Fig.26). Histological analyses 
showed that important histological hallmarks for GBM malignancy were 
observed in control tumor tissues. In contrast, these malignant characteristics 
dramatically disappeared by nigericin treatment in vivo (Fig.27). Also, down-
regulation of Ki67 staining, by nigericin treatment in vivo (Fig.28). When the 
effect of nigericin on tumor cell growth in recipient mice bearing Tsc1Δ/Δ  or 
control mouse glioma cells were evaluated, I found that nigericin profoundly 
suppressed the growth of Tsc1-deficient tumors in vivo, consistent with in vitro 
results (Fig.29). In addition, when I evaluated the effects of other candidate 
agents on human GBM cells, I found that all of these compounds suppressed 
sphere formation (Fig.30,31). Then, auranofin was selected to perform an in vivo 
experiment. auranofin treatment of glioma-bearing mice resulted in a significant 
reduction in GBM growth in vivo (Fig.32). These data clearly indicate that this 
screening system based on an mTORC1-driven glioma model is useful for 
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